Skip to main
TENX

Tenax Therapeutics (TENX) Stock Forecast & Price Target

Tenax Therapeutics (TENX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Tenax Therapeutics is showing promising results in its phase three trials, specifically for its drug Levosimendan which has potential as a first-in-class treatment for acutely decompensated heart failure in hospitalized patients. With comparable biomarker data and secondary outcomes between the total LEVEL population and the subgroup of patients with lower 6WMT at baseline, there is confidence in the effectiveness of Levosimendan for all patients with pulmonary hypertension, not just those with lower walk distances at baseline.

Bears say

Tenax Therapeutics is a development-stage pharmaceutical company with a negative outlook due to the recent failure of its phase three trial for its prioritized product candidate, levosimendan, in patients with pulmonary hypertension. The company failed to demonstrate a clear association between baseline hemodynamic measures and improved responses on the 6MWT test, and its drug did not show significant improvement in exercise capacity or quality of life measures compared to placebo. The company is also facing regulatory and IP risks, as well as competition from other potential therapies in this therapeutic area. These factors, along with the company's uncertain path forward, have led to a reduction of projected sales and a lowered valuation for the stock.

Tenax Therapeutics (TENX) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenax Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenax Therapeutics (TENX) Forecast

Analysts have given Tenax Therapeutics (TENX) a Buy based on their latest research and market trends.

According to 6 analysts, Tenax Therapeutics (TENX) has a Buy consensus rating as of Sep 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenax Therapeutics (TENX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.